Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2020-12-15 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
IMFINZI NEW DOSE RECEIVES POSITIVE EU CHMP OPINION
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, submitted to the SEC as a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding a new dosing regimen for the drug Imfinzi. The content is primarily a corporate announcement about regulatory approval and clinical trial data, not a full financial report or earnings release. The document is over 11,000 characters, indicating it is not a brief announcement or a simple report publication notice. It does not contain financial statements or detailed financial analysis, so it is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a transcript, management report, or governance information. The nature of the document is a regulatory announcement about a drug approval and clinical data, which fits best under Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2020-12-15 English
Imfinzi new dose receives positive EU CHMP opinion
Legal Proceedings Report Classification · 99% confidence The document is clearly identified as an RNS announcement by the header 'RNS Number : 6753I' and the closing statement referencing RNS, the news service of the London Stock Exchange. The content describes a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding a new dosing option for the drug Imfinzi. This is a material, time-sensitive announcement related to regulatory/clinical progress, which fits the definition of a general regulatory announcement or news release that doesn't fit a more specific category like 10-K, ER, or CT. Since it is a regulatory news service release and not a full report or a specific corporate action like a dividend or director dealing, the most appropriate classification is Regulatory Filings (RNS). The document length (11,700 chars) is substantial, but the format and source tag it as an RNS release.
2020-12-15 English
425 Filing
Call Transcript Classification · 95% confidence The document is a detailed transcript of a presentation made by AstraZeneca and Alexion Pharmaceuticals executives to investors and analysts. It discusses a significant merger transaction, strategic rationale, pipeline details, and financial implications. The presence of multiple company executives, analysts, and the detailed discussion of the merger and business strategy indicate this is a call transcript of a conference call or investor presentation. The document is not a formal report like an annual or quarterly report, nor is it a brief announcement or regulatory filing. It is a full transcript of a presentation and Q&A session related to a major corporate transaction and business update. Therefore, the most appropriate classification is Call Transcript (CT).
2020-12-15 English
TRASTUZUMAB DERUXTECAN POSITIVE CHMP
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains a detailed announcement about the positive CHMP opinion recommending approval of trastuzumab deruxtecan for HER2-positive metastatic breast cancer in the EU. The document includes clinical trial results, regulatory status updates, and company information. It is not an annual or interim financial report, nor is it a transcript, audit, or management report. It is a regulatory announcement providing material information about a drug approval process and clinical trial outcomes. The document is lengthy (over 12,000 characters) and contains substantive content, not just a brief announcement or certification. Given the nature of the filing (Form 6-K) and the content focusing on regulatory and clinical trial updates, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-12-14 English
TRIXEO AEROSPHERE APPROVED IN THE EU FOR COPD
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the approval of Trixeo Aerosphere in the EU for COPD treatment, including clinical trial data and company background. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about the company’s product approval and clinical trial results. The length of the document (12,455 characters) and the detailed content confirm it is a substantive regulatory announcement rather than a brief notice or certification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-12-14 English
ASTRAZENECA TO ACQUIRE ALEXION PHARMACEUTICALS INC
M&A Activity Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC announcing its definitive agreement to acquire Alexion Pharmaceuticals Inc. It contains detailed information about the acquisition terms, strategic rationale, financial benefits, and financing arrangements. The document is not a full annual or quarterly report, nor is it an earnings release or a regulatory certification. It is a formal announcement of a merger and acquisition transaction, including financial and strategic details. Therefore, it fits the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids. The document length and content support this classification with high confidence.
2020-12-14 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.